Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Purchased by Bridge City Capital LLC

Bridge City Capital LLC increased its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 28.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 103,809 shares of the company’s stock after purchasing an additional 22,773 shares during the quarter. Bridge City Capital LLC’s holdings in Harmony Biosciences were worth $3,572,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in HRMY. GAMMA Investing LLC increased its stake in Harmony Biosciences by 92.6% in the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after purchasing an additional 436 shares in the last quarter. Mendota Financial Group LLC grew its holdings in Harmony Biosciences by 24,125.0% in the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock valued at $33,000 after purchasing an additional 965 shares during the last quarter. KBC Group NV increased its position in shares of Harmony Biosciences by 79.9% in the fourth quarter. KBC Group NV now owns 1,844 shares of the company’s stock valued at $63,000 after buying an additional 819 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Harmony Biosciences during the 3rd quarter worth $74,000. Finally, PNC Financial Services Group Inc. boosted its position in shares of Harmony Biosciences by 28.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company’s stock worth $80,000 after buying an additional 519 shares in the last quarter. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Insider Transactions at Harmony Biosciences

In other news, CFO Sandip Kapadia sold 1,775 shares of Harmony Biosciences stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $38.05, for a total transaction of $67,538.75. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Jeffrey Dierks sold 10,507 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $37.01, for a total transaction of $388,864.07. The disclosure for this sale can be found here. Insiders sold 72,452 shares of company stock valued at $2,831,679 over the last quarter. Company insiders own 30.80% of the company’s stock.

Harmony Biosciences Trading Up 1.1 %

Shares of HRMY stock opened at $35.28 on Friday. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $28.14 and a fifty-two week high of $41.61. The firm’s 50 day moving average price is $36.42 and its two-hundred day moving average price is $35.58. The stock has a market cap of $2.02 billion, a price-to-earnings ratio of 16.72, a price-to-earnings-growth ratio of 0.47 and a beta of 0.82. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28.

Harmony Biosciences (NASDAQ:HRMY) last posted its earnings results on Tuesday, February 25th. The company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.11. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business had revenue of $201.30 million for the quarter, compared to analyst estimates of $201.25 million. During the same quarter in the previous year, the business posted $0.45 EPS. The business’s quarterly revenue was up 19.5% on a year-over-year basis. On average, analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft began coverage on shares of Harmony Biosciences in a research report on Tuesday, February 11th. They set a “buy” rating and a $55.00 target price for the company. Mizuho lifted their price objective on Harmony Biosciences from $42.00 to $44.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 18th. HC Wainwright lowered their target price on Harmony Biosciences from $75.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday, February 27th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $50.00 price target on shares of Harmony Biosciences in a report on Tuesday, February 25th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $53.33.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.